Safety setback for BTK blockers as FDA holds fenebrutinib trial

5 December 2023
genentech-large

Roche (ROG: SIX) subsidiary Genentech has provided an update on its multiple sclerosis program, revealing a partial trial stoppage for the oral BTK inhibitor fenebrutinib.

The US Food and Drug Administration has stopped enrollment in the Phase III FENhance I trial, after two recent cases of elevated liver enzymes were discovered.

Genentech said the data were “suggestive of drug-induced liver injury,” a worry that has affected rival BTK blockers under development by Sanofi (Euronext: SAN) and Merck KGaA (MRK: DE).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology